EP2303837A2 - Nouveaux composes, leur utilisation comme medicaments, et leur procede de preparation - Google Patents
Nouveaux composes, leur utilisation comme medicaments, et leur procede de preparationInfo
- Publication number
- EP2303837A2 EP2303837A2 EP09794039A EP09794039A EP2303837A2 EP 2303837 A2 EP2303837 A2 EP 2303837A2 EP 09794039 A EP09794039 A EP 09794039A EP 09794039 A EP09794039 A EP 09794039A EP 2303837 A2 EP2303837 A2 EP 2303837A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- independently
- formula
- compound
- group
- another
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 324
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title abstract description 20
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 86
- 239000000460 chlorine Substances 0.000 claims abstract description 85
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 83
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 45
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 45
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 44
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 43
- 150000002367 halogens Chemical class 0.000 claims abstract description 43
- 239000011630 iodine Substances 0.000 claims abstract description 41
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 41
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 30
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 27
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 94
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 75
- 150000003839 salts Chemical class 0.000 claims description 63
- 239000002253 acid Substances 0.000 claims description 61
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 52
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 47
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 230000007170 pathology Effects 0.000 claims description 24
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 125000006239 protecting group Chemical group 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 20
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 150000001412 amines Chemical class 0.000 claims description 17
- 208000035143 Bacterial infection Diseases 0.000 claims description 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 14
- 208000030852 Parasitic disease Diseases 0.000 claims description 14
- 239000013543 active substance Substances 0.000 claims description 14
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 14
- 239000011737 fluorine Substances 0.000 claims description 14
- 229910052731 fluorine Inorganic materials 0.000 claims description 14
- 206010017533 Fungal infection Diseases 0.000 claims description 13
- 208000031888 Mycoses Diseases 0.000 claims description 13
- 208000036142 Viral infection Diseases 0.000 claims description 13
- 230000002538 fungal effect Effects 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 238000003482 Pinner synthesis reaction Methods 0.000 claims description 5
- 238000010511 deprotection reaction Methods 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 244000045947 parasite Species 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 241000710781 Flaviviridae Species 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- 241000709664 Picornaviridae Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 206010063409 Acarodermatitis Diseases 0.000 claims description 2
- 241000712892 Arenaviridae Species 0.000 claims description 2
- 241000228212 Aspergillus Species 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241001480035 Epidermophyton Species 0.000 claims description 2
- 241000700586 Herpesviridae Species 0.000 claims description 2
- 241001480037 Microsporum Species 0.000 claims description 2
- 241001399426 Myas Species 0.000 claims description 2
- 241000712464 Orthomyxoviridae Species 0.000 claims description 2
- 241000701945 Parvoviridae Species 0.000 claims description 2
- 241000150350 Peribunyaviridae Species 0.000 claims description 2
- 241000142787 Pneumocystis jirovecii Species 0.000 claims description 2
- 241000700625 Poxviridae Species 0.000 claims description 2
- 241000702247 Reoviridae Species 0.000 claims description 2
- 241000711931 Rhabdoviridae Species 0.000 claims description 2
- 241000447727 Scabies Species 0.000 claims description 2
- 241000710924 Togaviridae Species 0.000 claims description 2
- 241000223238 Trichophyton Species 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 238000011905 homologation Methods 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 208000028454 lice infestation Diseases 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 208000005687 scabies Diseases 0.000 claims description 2
- 241000700739 Hepadnaviridae Species 0.000 claims 1
- 241000242594 Platyhelminthes Species 0.000 claims 1
- 208000035472 Zoonoses Diseases 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 206010048282 zoonosis Diseases 0.000 claims 1
- 150000001409 amidines Chemical class 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 238000005481 NMR spectroscopy Methods 0.000 description 39
- 238000000921 elemental analysis Methods 0.000 description 36
- 239000000203 mixture Substances 0.000 description 28
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- -1 Amino acid salts Chemical class 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 150000001335 aliphatic alkanes Chemical class 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- VBZCVIBBTVSYSO-UHFFFAOYSA-N ethyl propanimidate Chemical compound CCOC(=N)CC VBZCVIBBTVSYSO-UHFFFAOYSA-N 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000001704 evaporation Methods 0.000 description 13
- 230000008020 evaporation Effects 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 229960003260 chlorhexidine Drugs 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 229960001915 hexamidine Drugs 0.000 description 8
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000004966 cyanoalkyl group Chemical group 0.000 description 6
- 231100000263 cytotoxicity test Toxicity 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 230000005587 bubbling Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- ATWLRNODAYAMQS-UHFFFAOYSA-N 1,1-dibromopropane Chemical compound CCC(Br)Br ATWLRNODAYAMQS-UHFFFAOYSA-N 0.000 description 3
- RQXXCWHCUOJQGR-UHFFFAOYSA-N 1,1-dichlorohexane Chemical compound CCCCCC(Cl)Cl RQXXCWHCUOJQGR-UHFFFAOYSA-N 0.000 description 3
- KUNAKYAUWIYPPF-UHFFFAOYSA-N 2-[2-[4-[3-[4-[2-(diaminomethylideneamino)ethyl]phenoxy]propoxy]phenyl]ethyl]guanidine Chemical compound C1=CC(CCNC(=N)N)=CC=C1OCCCOC1=CC=C(CCNC(N)=N)C=C1 KUNAKYAUWIYPPF-UHFFFAOYSA-N 0.000 description 3
- SWTOHXMMFFFWNU-UHFFFAOYSA-N 2-[2-[4-[6-[4-[2-(diaminomethylideneamino)ethyl]phenoxy]hexoxy]phenyl]ethyl]guanidine Chemical compound C1=CC(CCNC(=N)N)=CC=C1OCCCCCCOC1=CC=C(CCNC(N)=N)C=C1 SWTOHXMMFFFWNU-UHFFFAOYSA-N 0.000 description 3
- ZANVYTSSWLMXML-UHFFFAOYSA-N 2-[2-[4-[[4-[2-(diaminomethylideneamino)ethyl]phenoxy]methoxy]phenyl]ethyl]guanidine Chemical compound C1=CC(CCNC(=N)N)=CC=C1OCOC1=CC=C(CCNC(N)=N)C=C1 ZANVYTSSWLMXML-UHFFFAOYSA-N 0.000 description 3
- KDMJGLYRWRHKJS-UHFFFAOYSA-N 3-(4-hydroxyphenyl)propanenitrile Chemical compound OC1=CC=C(CCC#N)C=C1 KDMJGLYRWRHKJS-UHFFFAOYSA-N 0.000 description 3
- WTERQJSRCHJTBV-UHFFFAOYSA-N 3-[4-[4-[4-(3-amino-3-iminopropyl)phenoxy]butoxy]phenyl]propanimidamide Chemical compound C1=CC(CCC(=N)N)=CC=C1OCCCCOC1=CC=C(CCC(N)=N)C=C1 WTERQJSRCHJTBV-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 108010015899 Glycopeptides Proteins 0.000 description 3
- 102000002068 Glycopeptides Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 2
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 2
- FSTKSTMFMLANPA-UHFFFAOYSA-N 1,1-dibromononane Chemical compound CCCCCCCCC(Br)Br FSTKSTMFMLANPA-UHFFFAOYSA-N 0.000 description 2
- STBMZSJLFYGOJU-UHFFFAOYSA-N 1,1-dibromooctane Chemical compound CCCCCCCC(Br)Br STBMZSJLFYGOJU-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- BXXWFOGWXLJPPA-UHFFFAOYSA-N 2,3-dibromobutane Chemical compound CC(Br)C(C)Br BXXWFOGWXLJPPA-UHFFFAOYSA-N 0.000 description 2
- NESOFQBTOBXBDM-UHFFFAOYSA-N 2-[2-[4-[10-[4-[2-(diaminomethylideneamino)ethyl]phenoxy]decoxy]phenyl]ethyl]guanidine Chemical compound C1=CC(CCN=C(N)N)=CC=C1OCCCCCCCCCCOC1=CC=C(CCN=C(N)N)C=C1 NESOFQBTOBXBDM-UHFFFAOYSA-N 0.000 description 2
- NPNNNVGMXLGXTD-UHFFFAOYSA-N 2-[2-[4-[4-[4-[2-(diaminomethylideneamino)ethyl]phenoxy]butoxy]phenyl]ethyl]guanidine Chemical compound C1=CC(CCNC(=N)N)=CC=C1OCCCCOC1=CC=C(CCNC(N)=N)C=C1 NPNNNVGMXLGXTD-UHFFFAOYSA-N 0.000 description 2
- QQVYKXHKDQNPQW-UHFFFAOYSA-N 2-[2-[4-[7-[4-[2-(diaminomethylideneamino)ethyl]phenoxy]heptoxy]phenyl]ethyl]guanidine Chemical compound C1=CC(CCNC(=N)N)=CC=C1OCCCCCCCOC1=CC=C(CCNC(N)=N)C=C1 QQVYKXHKDQNPQW-UHFFFAOYSA-N 0.000 description 2
- QQGDSOMKXOXVHD-UHFFFAOYSA-N 2-[2-[4-[8-[4-[2-(diaminomethylideneamino)ethyl]phenoxy]octoxy]phenyl]ethyl]guanidine Chemical compound C1=CC(CCNC(=N)N)=CC=C1OCCCCCCCCOC1=CC=C(CCNC(N)=N)C=C1 QQGDSOMKXOXVHD-UHFFFAOYSA-N 0.000 description 2
- SHWSOAOYINKAEM-UHFFFAOYSA-N 2-[2-[4-[9-[4-[2-(diaminomethylideneamino)ethyl]phenoxy]nonoxy]phenyl]ethyl]guanidine Chemical compound C1=CC(CCNC(=N)N)=CC=C1OCCCCCCCCCOC1=CC=C(CCNC(N)=N)C=C1 SHWSOAOYINKAEM-UHFFFAOYSA-N 0.000 description 2
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 2
- NTIGNJOEVBTPJJ-UHFFFAOYSA-N 3,3-dibromopentane Chemical compound CCC(Br)(Br)CC NTIGNJOEVBTPJJ-UHFFFAOYSA-N 0.000 description 2
- NGIRSBPPKZZIKE-UHFFFAOYSA-N 3-[4-[10-[4-(2-cyanoethyl)phenoxy]decoxy]phenyl]propanenitrile Chemical compound C1=CC(CCC#N)=CC=C1OCCCCCCCCCCOC1=CC=C(CCC#N)C=C1 NGIRSBPPKZZIKE-UHFFFAOYSA-N 0.000 description 2
- UGFXVWMHFLCMAJ-UHFFFAOYSA-N 3-[4-[10-[4-(3-amino-3-iminopropyl)phenoxy]decoxy]phenyl]propanimidamide Chemical compound C1=CC(CCC(=N)N)=CC=C1OCCCCCCCCCCOC1=CC=C(CCC(N)=N)C=C1 UGFXVWMHFLCMAJ-UHFFFAOYSA-N 0.000 description 2
- XECRTAGGXDSJFV-UHFFFAOYSA-N 3-[4-[3-[4-(3-amino-3-iminopropyl)phenoxy]propoxy]phenyl]propanimidamide Chemical compound C1=CC(CCC(=N)N)=CC=C1OCCCOC1=CC=C(CCC(N)=N)C=C1 XECRTAGGXDSJFV-UHFFFAOYSA-N 0.000 description 2
- VOVQRSHZNVCTJO-UHFFFAOYSA-N 3-[4-[4-[4-(2-cyanoethyl)phenoxy]butoxy]phenyl]propanenitrile Chemical compound C1=CC(CCC#N)=CC=C1OCCCCOC1=CC=C(CCC#N)C=C1 VOVQRSHZNVCTJO-UHFFFAOYSA-N 0.000 description 2
- KLVNFWVCHMPPLO-UHFFFAOYSA-N 3-[4-[5-[4-(2-cyanoethyl)phenoxy]pentoxy]phenyl]propanenitrile Chemical compound C1=CC(CCC#N)=CC=C1OCCCCCOC1=CC=C(CCC#N)C=C1 KLVNFWVCHMPPLO-UHFFFAOYSA-N 0.000 description 2
- WDQSYAWYXXFWFG-UHFFFAOYSA-N 3-[4-[5-[4-(3-amino-3-iminopropyl)phenoxy]pentoxy]phenyl]propanimidamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(CCC(=N)N)=CC=C1OCCCCCOC1=CC=C(CCC(N)=N)C=C1 WDQSYAWYXXFWFG-UHFFFAOYSA-N 0.000 description 2
- OMVRYRZNCVMECF-UHFFFAOYSA-N 3-[4-[6-[4-(2-cyanoethyl)phenoxy]hexoxy]phenyl]propanenitrile Chemical compound C1=CC(CCC#N)=CC=C1OCCCCCCOC1=CC=C(CCC#N)C=C1 OMVRYRZNCVMECF-UHFFFAOYSA-N 0.000 description 2
- KWOMIUOTJVDWFC-UHFFFAOYSA-N 3-[4-[6-[4-(3-amino-3-iminopropyl)phenoxy]hexoxy]phenyl]propanimidamide dihydrochloride Chemical compound C(N)(=N)CCC1=CC=C(OCCCCCCOC2=CC=C(C=C2)CCC(N)=N)C=C1.Cl.Cl KWOMIUOTJVDWFC-UHFFFAOYSA-N 0.000 description 2
- XZYHGRXAIFFLLN-UHFFFAOYSA-N 3-[4-[7-[4-(3-amino-3-iminopropyl)phenoxy]heptoxy]phenyl]propanimidamide Chemical compound C1=CC(CCC(=N)N)=CC=C1OCCCCCCCOC1=CC=C(CCC(N)=N)C=C1 XZYHGRXAIFFLLN-UHFFFAOYSA-N 0.000 description 2
- TYLCRYGAVTULIV-UHFFFAOYSA-N 3-[4-[8-[4-(2-cyanoethyl)phenoxy]octoxy]phenyl]propanenitrile Chemical compound C1=CC(CCC#N)=CC=C1OCCCCCCCCOC1=CC=C(CCC#N)C=C1 TYLCRYGAVTULIV-UHFFFAOYSA-N 0.000 description 2
- PNRNTKLDEFWBEX-UHFFFAOYSA-N 3-[4-[8-[4-(3-amino-3-iminopropyl)phenoxy]octoxy]phenyl]propanimidamide Chemical compound C1=CC(CCC(=N)N)=CC=C1OCCCCCCCCOC1=CC=C(CCC(N)=N)C=C1 PNRNTKLDEFWBEX-UHFFFAOYSA-N 0.000 description 2
- HELUQWVOMNSOJW-UHFFFAOYSA-N 3-[4-[9-[4-(2-cyanoethyl)phenoxy]nonoxy]phenyl]propanenitrile Chemical compound C1=CC(CCC#N)=CC=C1OCCCCCCCCCOC1=CC=C(CCC#N)C=C1 HELUQWVOMNSOJW-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- TZFKFDQPHRPMKH-UHFFFAOYSA-N 4,4-dibromoheptane Chemical compound CCCC(Br)(Br)CCC TZFKFDQPHRPMKH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- JBPCPICLPOJYJV-UHFFFAOYSA-N N(C(=N)N)CCC1=CC=C(OCCCCCC)C=C1 Chemical compound N(C(=N)N)CCC1=CC=C(OCCCCCC)C=C1 JBPCPICLPOJYJV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 108010053950 Teicoplanin Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000000909 amidinium group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 125000000950 dibromo group Chemical group Br* 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- KGMXPXPXPAAUMD-UHFFFAOYSA-N propane;dihydrochloride Chemical compound Cl.Cl.CCC KGMXPXPXPAAUMD-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical group [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001608 teicoplanin Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- RDTDGCFHLLTGQL-UHFFFAOYSA-N tert-butyl 2-amino-3-[4-[6-[4-[2-amino-3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]phenoxy]hexoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC(C)(C)C)=CC=C1OCCCCCCOC1=CC=C(CC(N)C(=O)OC(C)(C)C)C=C1 RDTDGCFHLLTGQL-UHFFFAOYSA-N 0.000 description 2
- ILNOTKMMDBWGOK-UHFFFAOYSA-N tert-butyl n-[2-(4-hydroxyphenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=CC=C(O)C=C1 ILNOTKMMDBWGOK-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical group C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- HFVIYAZBVIGNAN-UHFFFAOYSA-N 1,1-dibromodecane Chemical compound CCCCCCCCCC(Br)Br HFVIYAZBVIGNAN-UHFFFAOYSA-N 0.000 description 1
- SAWCWRKKWROPRB-UHFFFAOYSA-N 1,1-dibromohexane Chemical compound CCCCCC(Br)Br SAWCWRKKWROPRB-UHFFFAOYSA-N 0.000 description 1
- IXADHCVQNVXURI-UHFFFAOYSA-N 1,1-dichlorodecane Chemical compound CCCCCCCCCC(Cl)Cl IXADHCVQNVXURI-UHFFFAOYSA-N 0.000 description 1
- YUMNZEWYPUBSQA-UHFFFAOYSA-N 1-(chloromethoxy)octane Chemical compound CCCCCCCCOCCl YUMNZEWYPUBSQA-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- KYHSTQLVLYUKFI-UHFFFAOYSA-N 2-[2-(4-butoxyphenyl)ethyl]guanidine Chemical compound N(C(=N)N)CCC1=CC=C(OCCCC)C=C1 KYHSTQLVLYUKFI-UHFFFAOYSA-N 0.000 description 1
- VQTRKLQVLFPUCT-UHFFFAOYSA-N 2-[2-(4-dodecoxyphenyl)ethyl]guanidine Chemical compound N(C(=N)N)CCC1=CC=C(OCCCCCCCCCCCC)C=C1 VQTRKLQVLFPUCT-UHFFFAOYSA-N 0.000 description 1
- ZFTPDROAROXNDO-UHFFFAOYSA-N 2-[2-(4-heptoxyphenyl)ethyl]guanidine Chemical compound CCCCCCCOC1=CC=C(CCNC(N)=N)C=C1 ZFTPDROAROXNDO-UHFFFAOYSA-N 0.000 description 1
- UPFGKLBIWCGVRY-UHFFFAOYSA-N 2-[2-(4-pentoxyphenyl)ethyl]guanidine Chemical compound N(C(=N)N)CCC1=CC=C(OCCCCC)C=C1 UPFGKLBIWCGVRY-UHFFFAOYSA-N 0.000 description 1
- FBDFIAVPXZQTMW-UHFFFAOYSA-N 2-[2-[4-[12-[4-[2-(diaminomethylideneamino)ethyl]phenoxy]dodecoxy]phenyl]ethyl]guanidine Chemical compound C1=CC(CCNC(=N)N)=CC=C1OCCCCCCCCCCCCOC1=CC=C(CCNC(N)=N)C=C1 FBDFIAVPXZQTMW-UHFFFAOYSA-N 0.000 description 1
- WJKXYOHOGIIPAA-UHFFFAOYSA-N 2-[2-[4-[5-[4-[2-(diaminomethylideneamino)ethyl]phenoxy]pentoxy]phenyl]ethyl]guanidine Chemical compound C1=CC(CCNC(=N)N)=CC=C1OCCCCCOC1=CC=C(CCNC(N)=N)C=C1 WJKXYOHOGIIPAA-UHFFFAOYSA-N 0.000 description 1
- RLSPHJLMBXYZDV-UHFFFAOYSA-N 2-[4-[6-[4-(2-aminoethyl)phenoxy]hexoxy]phenyl]ethanamine Chemical compound C1=CC(CCN)=CC=C1OCCCCCCOC1=CC=C(CCN)C=C1 RLSPHJLMBXYZDV-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FQCAYNPTJRZTOU-UHFFFAOYSA-N 3-[4-[10-[4-(3-amino-3-iminopropyl)phenoxy]decoxy]phenyl]propanimidamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(CCC(=N)N)=CC=C1OCCCCCCCCCCOC1=CC=C(CCC(N)=N)C=C1 FQCAYNPTJRZTOU-UHFFFAOYSA-N 0.000 description 1
- XLYFVZLWGJSTCG-UHFFFAOYSA-N 3-[4-[3-[4-(2-cyanoethyl)phenoxy]propoxy]phenyl]propanenitrile Chemical compound C1=CC(CCC#N)=CC=C1OCCCOC1=CC=C(CCC#N)C=C1 XLYFVZLWGJSTCG-UHFFFAOYSA-N 0.000 description 1
- VDWHBWNWPPQXAZ-UHFFFAOYSA-N 3-[4-[5-[4-(3-amino-3-iminopropyl)phenoxy]pentoxy]phenyl]propanimidamide Chemical compound C1=CC(CCC(=N)N)=CC=C1OCCCCCOC1=CC=C(CCC(N)=N)C=C1 VDWHBWNWPPQXAZ-UHFFFAOYSA-N 0.000 description 1
- BJNQIRBJBHCRKE-UHFFFAOYSA-N 3-[4-[6-[4-(3-amino-3-iminopropyl)phenoxy]hexoxy]phenyl]propanimidamide Chemical compound C1=CC(CCC(=N)N)=CC=C1OCCCCCCOC1=CC=C(CCC(N)=N)C=C1 BJNQIRBJBHCRKE-UHFFFAOYSA-N 0.000 description 1
- HNNXCKFWSSGMQE-UHFFFAOYSA-N 3-[4-[7-[4-(2-cyanoethyl)phenoxy]heptoxy]phenyl]propanenitrile Chemical compound C1=CC(CCC#N)=CC=C1OCCCCCCCOC1=CC=C(CCC#N)C=C1 HNNXCKFWSSGMQE-UHFFFAOYSA-N 0.000 description 1
- OUPDRBYHLNVWII-UHFFFAOYSA-N 3-[4-[7-[4-(3-amino-3-iminopropyl)phenoxy]heptoxy]phenyl]propanimidamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(CCC(=N)N)=CC=C1OCCCCCCCOC1=CC=C(CCC(N)=N)C=C1 OUPDRBYHLNVWII-UHFFFAOYSA-N 0.000 description 1
- RHYZLAYIRJUUQM-UHFFFAOYSA-N 3-[4-[9-[4-(3-amino-3-iminopropyl)phenoxy]nonoxy]phenyl]propanimidamide Chemical compound C1=CC(CCC(=N)N)=CC=C1OCCCCCCCCCOC1=CC=C(CCC(N)=N)C=C1 RHYZLAYIRJUUQM-UHFFFAOYSA-N 0.000 description 1
- OCACJLWARDJXKY-UHFFFAOYSA-N 3-[4-[9-[4-(3-amino-3-iminopropyl)phenoxy]nonoxy]phenyl]propanimidamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(CCC(=N)N)=CC=C1OCCCCCCCCCOC1=CC=C(CCC(N)=N)C=C1 OCACJLWARDJXKY-UHFFFAOYSA-N 0.000 description 1
- OFMIQOPQAGFZDU-UHFFFAOYSA-N 3-[4-[[4-(2-cyanoethyl)phenoxy]methoxy]phenyl]propanenitrile Chemical compound C1=CC(CCC#N)=CC=C1OCOC1=CC=C(CCC#N)C=C1 OFMIQOPQAGFZDU-UHFFFAOYSA-N 0.000 description 1
- IBOFVQJTBBUKMU-UHFFFAOYSA-N 4,4'-methylene-bis-(2-chloroaniline) Chemical compound C1=C(Cl)C(N)=CC=C1CC1=CC=C(N)C(Cl)=C1 IBOFVQJTBBUKMU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- DZGQBQYCLPENOV-UHFFFAOYSA-N C(#N)CCC1=CC=C(OCCCCCCC)C=C1 Chemical compound C(#N)CCC1=CC=C(OCCCCCCC)C=C1 DZGQBQYCLPENOV-UHFFFAOYSA-N 0.000 description 1
- XGKMMSPEQSHAJC-UHFFFAOYSA-N C(N)(=N)CCC1=CC=C(OCCCCCCCCC)C=C1 Chemical compound C(N)(=N)CCC1=CC=C(OCCCCCCCCC)C=C1 XGKMMSPEQSHAJC-UHFFFAOYSA-N 0.000 description 1
- PLRHBMJHARPJLJ-UHFFFAOYSA-N C(N)(=N)CCC1=CC=C(OCCCCCCCCOC2=CC=C(C=C2)CCC(N)=N)C=C1.Cl.Cl Chemical compound C(N)(=N)CCC1=CC=C(OCCCCCCCCOC2=CC=C(C=C2)CCC(N)=N)C=C1.Cl.Cl PLRHBMJHARPJLJ-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- VRVXHTYFJZJSIQ-UHFFFAOYSA-N Cl.Cl.C(N)(=N)CCC1=CC=C(OCCCOC2=CC=C(C=C2)CCC(N)=N)C=C1 Chemical compound Cl.Cl.C(N)(=N)CCC1=CC=C(OCCCOC2=CC=C(C=C2)CCC(N)=N)C=C1 VRVXHTYFJZJSIQ-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000943303 Enterococcus faecalis ATCC 29212 Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 238000001321 HNCO Methods 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- SKDVWSAUHIVZSG-UHFFFAOYSA-N N(C(=N)N)CCC1=CC=C(OC(CCCCCCCCC)OC2=CC=C(C=C2)CCNC(=N)N)C=C1 Chemical compound N(C(=N)N)CCC1=CC=C(OC(CCCCCCCCC)OC2=CC=C(C=C2)CCNC(=N)N)C=C1 SKDVWSAUHIVZSG-UHFFFAOYSA-N 0.000 description 1
- PQDALZYQTLNWMK-UHFFFAOYSA-N N(C(=N)N)CCC1=CC=C(OCCCCCCCCC)C=C1 Chemical compound N(C(=N)N)CCC1=CC=C(OCCCCCCCCC)C=C1 PQDALZYQTLNWMK-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- RERZISQGOCYBPU-UHFFFAOYSA-N butane;dihydrochloride Chemical compound Cl.Cl.CCCC RERZISQGOCYBPU-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- SZDZEUWZYMEIGB-UHFFFAOYSA-N decane;dihydrochloride Chemical compound Cl.Cl.CCCCCCCCCC SZDZEUWZYMEIGB-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- HKYGSMOFSFOEIP-UHFFFAOYSA-N dichloro(dichloromethoxy)methane Chemical compound ClC(Cl)OC(Cl)Cl HKYGSMOFSFOEIP-UHFFFAOYSA-N 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- NOAADQGAIOTYSP-UHFFFAOYSA-N heptane;dihydrochloride Chemical compound Cl.Cl.CCCCCCC NOAADQGAIOTYSP-UHFFFAOYSA-N 0.000 description 1
- TWRQCVNFACGORI-UHFFFAOYSA-N hexane;dihydrochloride Chemical compound Cl.Cl.CCCCCC TWRQCVNFACGORI-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- KIMVTSGNCBGHES-UHFFFAOYSA-N octane;dihydrochloride Chemical compound Cl.Cl.CCCCCCCC KIMVTSGNCBGHES-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical group CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DDWNLZAZYDDEHF-UHFFFAOYSA-N tert-butyl n-[(e)-n'-(trifluoromethylsulfonyl)carbamimidoyl]carbamate Chemical compound CC(C)(C)OC(=O)N\C(N)=N\S(=O)(=O)C(F)(F)F DDWNLZAZYDDEHF-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 101150037181 vanB gene Proteins 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
Definitions
- Novel compounds their use as medicaments, and process for their preparation
- the invention relates to novel compounds, their use as medicaments and their method of preparation.
- antiseptics and / or antibiotics are known and marketed, for example hexamidine and chlorhexidine.
- NSS nosocomial infections
- the agents responsible for IN can be bacteria, viruses or fungi.
- IN means any infection occurring within at least 48 hours (for bacterial infections) or within a period corresponding to the incubation period of the germ (for viral and fungal infections) after admission or at the following a hospitalization, and if she was absent on admission to the hospital.
- the nosocomial character of an infection of the surgical site is asserted if it occurs within 30 days after the intervention, or in the year if it involves the implantation of foreign material (prosthesis, implant), and this although the patient is no longer hospitalized.
- NNs are worrying because of their significant morbidity, associated mortality, significant additional hospital costs and the emergence of bacteria resistant to several families of antibiotics (BMR: Multi-Resistant Bacteria).
- NAs urinary tract infections (30%), respiratory infections (15%), surgical site infections (14%), and skin and soft tissue infections (10%).
- bacteria appear on the front line. The most commonly involved are Escherichia coli (25%) (intestinal commensal flora bacterium, responsible for urinary tract infections), Staphylococcus aureus (19%) (commensal cutaneous and nasal flora bacterium, responsible for skin infections and surgical site), Pseudomonas aeruginosa (10%) (opportunistic bacterium, responsible for severe pneumonias and skin infections), Enterococcus spp (6%) (intestinal commensal flora bacterium mainly responsible for urinary tract infections).
- MRSA Meticillin-Resistant Staphylococcus aureus
- glycopeptide-resistant enterococci (10%) (Vancomycin-resistant enterococci: vancomycin is a member of the glycopeptide family with teicoplanin), (iii) Pseudomonas aeruginosa resistant to cephalosporins. 3rd generation
- One aspect of the invention is to provide novel compounds for combating bacterial, viral, fungal and parasitic infections.
- One aspect of the invention relates to the use of compounds for the preparation of a medicament for the treatment of bacterial, viral, fungal and parasitic infections.
- the invention relates to the use of at least one compound of formula
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'independently of one another represent integers from 0 to 8, especially 1 to 8, - q and q 'represent, independently of each other, integers from 0 to 2, p and p' independently of one another represent integers from 0 to 4, - A and A 'independently represent one of the other a CH 2 group, an NH group or a NR "group, in which R" is an alkyl group of 1 to 3 carbon atoms, linear or branched, - B and B 'represent independently one of the another an oxygen atom or a CH 2 group,
- R and R ' are, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or a physiologically acceptable acid salt derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH),
- linear or branched alkyl group of 1 to 3 carbon atoms denotes methyl, ethyl, n-propyl and isopropyl groups.
- physiologically acceptable acid salt means that the compounds of the formula (I), defined above, may exist in the form of amidinium (when A and / or A 'are -CH 2 -) or guanidinium (when A and / or A 'represents (nt) NH or NR ”) by reaction of an inorganic acid or an organic acid with a compound of formula (I).
- inorganic acids for obtaining physiologically acceptable salts include, but are not limited to, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, formic acid monohydrogenocarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, perchloric acid, sulfuric acid, monohydrogenosulfuric acid, hydroiodic acid.
- organic acids for obtaining physiologically acceptable salts include, but are not limited to, acetic acid, lactic acid, propionic acid, butyric acid, isobutyric acid, lactic acid, palmic acid, maleic acid, glutamic acid, hydroxymaleic acid, malonic acid, benzoic acid, succinic acid, glycolic acid, suberic acid, fumaric acid, mandelic acid, phthalic acid, salicylic acid, benzenesulfonic acid, toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, hydroxynaphthoic acid.
- Amino acid salts such as arginates and their equivalents are also included as well as salts of organic acids such as glucuronic acid or galacturonic acid and their equivalents (see, for example, Berge et al, " Pharmaceutical Salts, "Journal of Pharmaceutical Science, 1977, 66, 1-19).
- n represents an integer from 1 to 12
- n means all integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12.
- m and m independently of one another represent integers from 0 to 8 "denote all integers 0, 1, 2, 3, 4, 5, 6, 7 and 8. This definition is applies to formula (I) but also to the other formulas below.
- the invention also relates to the use of at least one compound of formula (I) below:
- n represents an integer from 1 to 12, especially from 1 to 8, m and m 'independently of one another represent integers from 2 to 8, q and q' independently represent one on the other hand integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4, - A and A' represent, independently of one another, a CH group 2 , an NH group or a NR "group, wherein R" is an alkyl group of 1 to 3 carbon atoms, linear or branched,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group; - R and R' are, independently of each other, a halogen, such as chlorine, bromine, iodine or fluorine, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or a physio-logically acceptable acid salt derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH), for the preparation of a medicament for the treatment of pathologies associated with bacterial, viral, fungal and parasitic infections.
- a halogen such as chlorine, bromine, iodine or fluorine
- an alkyl group of 1 to 3 carbon atoms linear or branched
- a physio-logically acceptable acid salt derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate
- the invention also relates to the use of at least one compound of formula (I) below:
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'are equal to 2, q and q' independently of one another represent integers from 0 to 2, p and p 'represent, independently of one another, integers from 0 to 4,
- a and A 'independently of one another are CH 2 , NH or NR ", wherein R" is straight or branched alkyl of 1 to 3 carbon atoms,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group
- R and R ' are independently of each other a halogen, such as chlorine, bromine, iodine or fluorine, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or a salt of physio-logically acceptable acid derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH),
- the invention also relates to the use of at least one compound of formula (I) below:
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'independently of one another represent integers from 0 to 8, especially 1 to 8, q and q'; are equal to 0, p and p 'represent, independently of one another, integers from 0 to 4,
- a and A 'independently of one another are CH 2 , NH or NR ", wherein R" is straight or branched alkyl of 1 to 3 carbon atoms,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group
- R and R ' are independently of each other a halogen, such as chlorine, bromine, iodine or fluorine, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or a salt of physio-logically acceptable acid derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH),
- the invention also relates to the use of at least one compound of formula (I)
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'represent, independently of one another, integers from 0 to 8, especially 1 to 8, q and q 'represent, independently of each other, integers from 0 to 2, p and p' are equal to 0,
- a and A 'independently of one another are CH 2 , NH or NR ", wherein R" is straight or branched alkyl of 1 to 3 carbon atoms,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group, or a physiologically acceptable acid salt derived from a compound of formula (I) such as a hydrochloride, a formate, trifluoroacetate or oxalate (HOOCCOOH),
- the invention also relates to the use of at least one compound of formula (I) below:
- n represents an integer from 1 to 12, especially from 1 to 8, m and m 'are equal to 2, - q and q' are equal to 0, p and p 'independently represent one of other integers from 0 to 4,
- a and A 'independently of one another are CH 2 , NH or NR ", wherein R" is straight or branched alkyl of 1 to 3 carbon atoms,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group
- R and R ' are independently of each other a halogen, such as chlorine, bromine, iodine or fluorine, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or a salt of physio-logically acceptable acid derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH), for the preparation of a medicament for the treatment of pathologies associated with bacterial, viral, fungal and parasitic infections.
- a halogen such as chlorine, bromine, iodine or fluorine
- an alkyl group of 1 to 3 carbon atoms linear or branched
- a salt of physio-logically acceptable acid derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH)
- the invention also relates to the use of at least one compound of formula (I) below:
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'are equal to 2, q and q' independently of one another represent integers from 0 to 2, p and p 'are equal to 0,
- a and A 'independently of one another are CH 2 , NH or NR ", wherein R" is straight or branched alkyl of 1 to 3 carbon atoms,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group, or a physiologically acceptable acid salt derived from a compound of formula (I) such as a hydrochloride, a formate, trifluoroacetate or oxalate (HOOCCOOH),
- the invention also relates to the use of at least one compound of formula (I) below:
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'independently of one another represent integers from 0 to 8, especially 1 to 8,
- a and A 'independently of one another are CH 2 , NH or NR ", wherein R" is straight or branched alkyl of 1 to 3 carbon atoms,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group, or a physiologically acceptable acid salt derived from a compound of formula (I) such as a hydrochloride, a formate, trifluoroacetate or oxalate (HOOCCOOH),
- the invention also relates to the use of at least one compound of formula (I) below:
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'are equal to 2, q and q' are equal to 0, - p and p 'are equal to 0,
- a and A 'independently of one another are CH 2 , NH or NR ", wherein R" is straight or branched alkyl of 1 to 3 carbon atoms,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group, or a physiologically acceptable acid salt derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH),
- the invention also relates to the use of at least one compound of formula (Ia) below:
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'independently of one another represent integers from 0 to 8, especially 1 to 8, q and q'; independently of one another represent integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4,
- a and A 'independently of one another represent an NH group or a group
- R is an alkyl group of 1 to 3 carbon atoms, linear or branched
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group
- R and R ' are independently of each other a halogen, such as chlorine, bromine, iodine or fluorine, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or a salt of physio-logically acceptable acid derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH), for the preparation of a medicament for the treatment of pathologies associated with bacterial infections, viral, fungal and parasitic.
- a halogen such as chlorine, bromine, iodine or fluorine
- an alkyl group of 1 to 3 carbon atoms linear or branched
- a salt of physio-logically acceptable acid derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH)
- the compounds of formula (Ia) correspond to the compounds of formula (I) in which A and A 'represent, independently of one another, an NH group or an NR "group.
- the formula of the compounds for the use as defined above is the following formula (II):
- B, B ', R, R', m, m ', n, p, p' are as defined above, and, - A and A 'represent, independently of one another, a CH 2 group, an NH group or a NR "group, in which R" is a linear or branched alkyl group of 1 to 3 carbon atoms, or a physiologically acceptable acid salt derived from a compound of formula (II) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- a compound of formula (II) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- B, B ', R, R', m, m ', n, p, p' are as defined above, and,
- a and A 'independently of one another are NH or NR ", wherein R" is linear or branched alkyl of 1 to 3 carbon atoms, or a physiologically acid salt; acceptable derivative of a compound of formula (IF) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- IF acceptable derivative of a compound of formula (IF) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- the formula of the compounds of formula (IF) corresponds to formula (Ia), in which q and q 'are equal to 0.
- R represents a CH 2 group, an NH group or a NR "group, in which R" is an alkyl group of 1 to 3 carbon atoms. carbon, linear or branched, or a physio-logically acceptable acid salt derived from a compound of formula (III) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH).
- a compound of formula (III) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH).
- the formula of the compounds of formula (III) corresponds to formula (II), in which: m and m 'on the one hand, and p and p' on the other hand, are equal, and, - A and A 'd on the one hand, and B and B 'on the other, represent the same atom or group.
- the compounds of formula (III) are symmetrical.
- the formula of the compounds for the use as defined above is the following formula (HF):
- B, R, m, n, p are as defined above, and, - A represents an NH group or a NR "group, in which R" is an alkyl group of 1 to 3 carbon atoms, linear or branched or a physiologically acceptable acid salt derived from a compound of formula (III) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- a compound of formula (III) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- the formula of the compounds of formula (HF) corresponds to the formula (IF), in which: m and m 'on the one hand, and p and p' on the other hand, are equal, and
- a and A 'on the one hand, and B and B' on the other hand, represent the same atom or group.
- the compounds of formula (HF) are symmetrical.
- the formula of the compound for use as defined above is the following formula (IV):
- n 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, or a physiologically acceptable acid salt derived from a compound of formula (IV)
- the formula of the compounds of formula (IV) corresponds to formula (III), in which A represents an NH group, B an oxygen atom, p is equal to 0 and m is equal to 2.
- the compounds of formula (IV) are symmetrical.
- the formula of the compound for use as defined above is the following formula 6:
- a physiologically acceptable acid salt derived from a compound of formula 6 such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- the formula of the compounds of formula 6 corresponds to formula (IV), wherein n is 6.
- the compound of formula 6 is symmetrical.
- the formula of the compound for the use as defined above is the formula (II) as defined above in which: m is different from m ', and / or p is different from p 'and / or R is different from R' and / or A is different from A 'and / or
- the compounds of the invention are involved in the treatment of pathologies caused by the bacteria of Table 1.
- Table 1 Bacteria causing pathologies treated with the compounds according to the invention.
- the compounds of the invention are involved in the treatment of pathologies caused by multidrug-resistant bacteria (BMR) responsible for nosocomial and / or community infections.
- BMR multidrug-resistant bacteria
- the compounds of the invention are involved in the treatment of pathologies caused by viruses belonging to different families, such as: viral hepatitis A, B & D, C (families of Picornaviridae, Hepadnavi ⁇ dae, Flaviviridae) ; AIDS, leukemia, cancer ... (Family Retroviridae); smallpox ... (Family Poxviridae); oral and / or genital herpes, chickenpox, shingles, mononucleosis, roselose, lymphoma ... (Family Herpesviridae); SARS, colds ...
- viruses belonging to different families such as: viral hepatitis A, B & D, C (families of Picornaviridae, Hepadnavi ⁇ dae, Flaviviridae) ; AIDS, leukemia, cancer ... (Family Retroviridae); smallpox ... (Family Poxviridae); oral
- the compounds of the invention are involved in the treatment of pathologies caused by fungi, in particular the following fungi: Candida spp., Aspergillus spp., Epidermophyton spp., Trichophyton spp., Microsporum spp. and Pneumocystis jiroveci.
- the compounds of the invention are involved in the treatment of pathologies caused by the parasites of Table 2.
- Table 2 Parasites causing pathologies treated with the compounds according to the invention.
- pathologies caused by parasites may for example be parasitic diseases due to protozoa or worms, scabies, myases and pediculosis.
- the invention relates to the compound of formula (VI) below:
- n represents an integer from 1 to 12, in particular from 1 to 8, q and q 'independently of one another represent integers from 0 to 2, p and p' independently of one another represent integers from 0 to 4,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group
- R and R ' represent, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched,
- R '" represents a hydrogen or a group protecting the amine function, chosen especially from the groups Boc, Fmoc, Bn, Z, if A and A' represent, independently of one another, a CH 2 group, then m and m 'independently of one another represent integers from 1 to 8, if A and A' independently of one another represent an NH group or a group
- a physiologically acceptable acid salt derived from a compound of formula (VI) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH),
- the new compounds defined above can be used according to the present invention.
- the compounds of formula (VI), with the exception of the two compounds above, are new.
- linear or branched alkyl group of 1 to 3 carbon atoms denotes methyl, ethyl, n-propyl and isopropyl groups.
- physiologically acceptable acid salt means that the compounds of the formula (I), defined above, may exist in the form of amidinium (when A and / or A 'are -CH 2 -) or guanidinium (when A and / or A 'represents (nt) NH or NR ”) by reaction of an inorganic acid or an organic acid with a compound of formula (I).
- inorganic acids for obtaining physiologically acceptable salts include, but are not limited to, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, formic acid, monohydrogenocarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, perchloric acid, sulfuric acid, monohydrogenosulfuric acid, hydroiodic acid.
- organic acids for obtaining physiologically acceptable salts include, but are not limited to, acetic acid, lactic acid, propionic acid, butyric acid, isobutyric acid, palmic acid, maleic acid, glutamic acid, hydroxymaleic acid, malonic acid, benzoic acid, succinic acid, glycolic acid, suberic acid, fumaric acid, mandelic acid, phthalic acid, salicylic acid, benzenesulfonic acid, ⁇ -toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, hydroxynaphthoic acid.
- Amino acid salts such as arginates and their equivalents are also included as well as salts of organic acids such as glucuronic acid or galacturonic acid and their equivalents (see, for example, Berge et al, " Pharmaceutical Salts, "Journal of Pharmaceutical Science, 1977, 66, 1-19).
- the invention relates to the compound of formula (VI) defined above, in which: m and m 'independently of one another represent integers from 2 to 8.
- the invention relates to the compound of formula
- the invention relates to the compound of formula (VI) defined above, in which: q and q 'are equal to 0.
- the invention relates to the compound of formula (VI) defined above, in which: p and p 'are equal to 0.
- the invention relates to the compound of formula (VI) defined above, in which: m and m 'are equal to 2, and q and q' are equal to 0 to 2.
- the invention relates to the compound of formula (VI) defined above, in which: m and m 'are equal to 2, and p and p' are equal to 0.
- the invention relates to the compound of formula (VI) defined above, in which: q and q 'are equal to 0, and p and p' are equal to 0.
- the invention relates to the compound of formula (VI) defined above, in which: m and m 'are equal to 2, q and q 'are 0, and p and p' are 0.
- the invention relates to the compound of formula (VI) defined above, in which: n represents an integer from 6 to 12, in particular from 8 to 10.
- the invention relates to the compound of formula (VI) defined above, in which: R, R 'represent, independently of one another, an alkyl group of 1 to 3 carbon atoms, linear or branched.
- the invention relates to the compound of formula (VI) defined above, in which: p and p 'are equal to 0.
- the invention relates to the compound of formula (VI) defined above, in which: n represents an integer ranging from 6 to 12, in particular from 8 to 10, and R, R 'represent independently from each other an alkyl group of 1 to 3 carbon atoms, linear or branched.
- the invention relates to the compound of formula (VI) defined above, in which: n represents an integer from 6 to 12, in particular from 8 to 10, and p and p 'are equal to to 0.
- the invention also relates to the compound of formula (VF) below:
- n represents an integer from 1 to 12, especially from 1 to 8, q and q 'independently of one another represent integers from 0 to 2, p and p' independently represent one of other integers from 0 to 4, B and B 'represent, independently of one another, an oxygen atom or a CH 2 group,
- R and R ' represent, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched,
- R '" represents a hydrogen or a group protecting the amine function, chosen in particular from the groups Boc, Fmoc, Bn, Z,
- a and A ' represent, independently of one another, an NH group or a NR "group, in which R" is an alkyl group of 1 to 3 carbon atoms, linear or branched, then m and m' represent independently from one another integers from 2 to 8,
- a physiologically acceptable acid salt derived from a compound of formula (VI) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH),
- the new compounds defined above can be used according to the present invention.
- the formula of the compounds of formula (VF) corresponds to formula (VI) with A and A 'representing, independently of one another, an NH group or an NR "group.
- the invention relates to compounds of formula
- n represents an integer from 1 to 12, especially from 1 to 8, q and q 'independently of one another represent integers from 0 to 2, p and p' independently represent one on the other, whole numbers from 0 to 4,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group
- R and R ' represent, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine, or an alkyl group of 1 to 3 carbon atoms, linear or branched, if A and A' independently of one another represent a group CH 2 , then m and m 'independently of one another represent integers from 1 to 8, if A and A' are independently of one another an NH group or a group
- a physiologically acceptable acid salt derived from a compound of formula (I) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH),
- the invention also relates to compounds of formula (Ia) below
- n represents an integer from 1 to 12, especially from 1 to 8, m and m 'independently of one another represent integers from 2 to 8, q and q' independently represent one of other integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4,
- a and A 'independently of one another represent an NH group or a group
- R is an alkyl group of 1 to 3 carbon atoms, linear or branched
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group; - R and R' are, independently of each other, a halogen, such as chlorine, bromine, iodine or fluorine, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or a physio-logically acceptable acid salt derived from a compound of formula (Ia) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH), the compounds of the following formulas being excluded:
- the formula of the compounds of formula (Ia) corresponds to the formula (VF), in which R "represents a hydrogen
- the formula of the compounds of formula (Ia) corresponds to formula (I), in which A and A 'represent independently from each other an NH group or a NR "group.
- the invention also relates to compounds of formula (Ib) below:
- n represents an integer from 1 to 12, especially from 1 to 8, m and m 'independently of one another represent integers from 1 to 8, q and q' independently represent one on the other, integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4, B and B' represent independently of each other an atom of oxygen or a CH 2 group, - R and R 'are independently of one another a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or a physiologically acceptable acid salt derived from a compound of formula (Ib) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH).
- a compound of formula (Ib) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCO
- the formula of the compounds of formula (Ib) corresponds to formula (I), in which A and A 'represent a CH 2 group.
- the new compounds defined above can be used according to the present invention.
- the invention relates to compounds of formula (II) below:
- a physiologically acceptable acid salt derived from a compound of formula (II) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- the formula of the compounds of formula (II) corresponds to formula (I), in which q and q 'are equal to 0.
- the compounds of formula (II) above, excluding the two compounds above, are new.
- the invention relates to compounds of formula (IF) below:
- a and A ' represent, independently of one another, an NH group or a NR "group, in which R" is an alkyl group of 1 to 3 carbon atoms, linear or branched, m and m' independently represent one of the other integers from 2 to 8,
- a physiologically acceptable acid salt derived from a compound of formula (IF) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH).
- a compound of formula (IF) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH).
- the formula of compounds of formula (IF) corresponds to formula (Ia), in which q and q 'are equal to 0.
- the formula of compounds (IF) corresponds to formula (II), in which A and A' represent independently of one another an NH group or a NR "group.
- the invention relates to compounds of formula (III) below:
- B, R, n, p are as defined above, and, if A represents a CH 2 group, then m represents an integer from 1 to 8, if A is an NH group or a NR "group, wherein R "is an alkyl group of 1 to 3 carbon atoms, linear or branched, then m represents an integer of 2 to 8,
- a physiologically acceptable acid salt derived from a compound of formula (III) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- the formula of the compounds of formula (III) corresponds to formula (II), in which: m and m 'on the one hand, and p and p' on the other hand, are equal, and A and A 'd' on the one hand, and B and B 'on the other, represent the same atom or group.
- the compounds of formula (III) are symmetrical.
- the compounds of formula (III) above (excluding the two compounds above) are new.
- the invention relates to compounds of formula (IH ') below:
- A represents an NH group or a NR "group, in which R" is an alkyl group of 1 to 3 carbon atoms, linear or branched, and
- n represents an integer from 2 to 8, or a physiologically acceptable acid salt derived from a compound of formula (HF) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH).
- HF a physiologically acceptable acid salt derived from a compound of formula (HF) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH).
- a and A 'on the one hand, and B and B' on the other hand, represent the same atom or group.
- the formula of the compounds (HF) corresponds to the formula (III), in which A and A 'represent, independently of one another, an NH group or an NR "group.
- the invention relates to compounds of formula (IV) below:
- n 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, or a physiologically acceptable acid salt derived from a compound of formula (IV) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- a physiologically acceptable acid salt derived from a compound of formula (IV) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- the formula of the compounds of formula (IV) corresponds to formula (III), in which A represents an NH group, B an oxygen atom, p is equal to 0 and m is equal to 2.
- the compounds of formula (IV) are symmetrical.
- the compounds of formula (IV) above (excluding the two compounds above) are new.
- the invention relates to compounds of formula 6 below:
- a physiologically acceptable acid salt derived from a compound of formula 6 such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- the formula of the compounds of formula 6 corresponds to formula (IV), wherein n is 6.
- the compound of formula 6 is symmetrical.
- the compound of formula 6 above is new.
- the invention relates to compounds of formula
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising as active substance at least one compound as defined above, in combination with a pharmaceutically acceptable vehicle.
- the pharmaceutical composition comprises as active substance:
- the first case corresponds to the compounds of formulas (VI), (I) and (II).
- the second case corresponds to the compounds of formulas (III), (IV) and 6, for which m is equal to m '. These compounds are soluble in aqueous solution.
- the pharmaceutical composition comprises as active substance: a compound as defined above, in particular for which the sum m + m '+ n is greater than 10, or a compound as defined above. above, for which the sum 2m + n is greater than 10, said pharmaceutical composition being formulated in hydroalcoholic solution.
- the first case corresponds to the compounds of formulas (VI), (I) and (II).
- the second case corresponds to the compounds of formulas (III), (IV) and 6, for which m is equal to m '.
- hydroalcoholic solution denotes a mixture of water and at least one alcohol, especially chosen from ethanol, isopropyl alcohol and benzyl alcohol.
- the pharmaceutical composition as defined above is orally administrable, and in said pharmaceutical composition, the active substance is at a concentration of about 0.1 to about 5 mg / kg body weight.
- the pharmaceutical composition as defined above is administrable topically, and in said pharmaceutical composition, the active substance is at a concentration of about 0.1% to about 1% relative to to the total weight in the pharmaceutical composition.
- topically means that the pharmaceutical composition is applied to localized locations, for example the skin or mucosa.
- compositions in capsule, tablet, powder, cream, lotion, aqueous or hydroalcoholic solution, mouthwash, eye drops, milk, foam, gel, spray or powder, for example.
- the invention also relates to the process for preparing a compound of formula (Ia) comprising the following steps of:
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'independently of one another represent integers from 2 to 8, q and q' independently represent one of the other integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4, A and A 'independently of one another represent an NH group or a group
- R is an alkyl group of 1 to 3 carbon atoms, linear or branched
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group
- R and R ' represent, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched,
- Y represents a protective group of amines, in particular Boc or Fmoc.
- n represents an integer from 1 to 12, especially from 1 to 8, m and m 'independently of one another represent integers from 2 to 8, q and q' independently represent one on the other integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4,
- a and A 'independently of one another represent an NH group or a group
- R is an alkyl group of 1 to 3 carbon atoms, linear or branched
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group
- R and R ' represent, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or,
- GP represents a Leaving Group such as -SR, -NTf or N and Y represents a protective group of amines, in particular Boc or Fmoc,
- n represents an integer from 1 to 12, especially from 1 to 8, - m and m 'independently of one another represent integers from 2 to 8, q and q' independently represent number of integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4, A and A' represent, independently of one another, an NH group or a group NR ", in which R" is an alkyl group of 1 to 3 carbon atoms, linear or branched,
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group
- R and R ' represent, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched,
- Y represents a protective group of amines, in particular Boc or Fmoc.
- n represents an integer from 1 to 12, especially from 1 to 8, m and m 'independently of one another represent integers from 2 to 8, q and q' independently represent number of integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4, - A and A' represent, independently of one another, a group NH or a group
- R is an alkyl group of 1 to 3 carbon atoms, linear or branched
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group; - R and R' are, independently of each other, a halogen, such as chlorine, bromine, iodine or fluorine, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or,
- an acid salt derived from a compound of formula (Ia) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH).
- linear or branched alkyl group of 1 to 3 carbon atoms denotes methyl, ethyl, n-propyl and isopropyl groups.
- the neutral form of the compound can be obtained by neutralizing the medium after reaction.
- the isolation of the compounds is facilitated when the compounds of formula (Ia), and in particular (XF), are in the form of acid salts.
- Step b) makes it possible to form guanidine function.
- This step is generally carried out in the presence of a base, for example triethylamine or diisopropylethylamine, and as an organic solvent, such as dichloromethane, although the use of other organic solvents is also possible, for example THF, methanol, acetonitrile, dioxane, or a mixture of these solvents.
- a base for example triethylamine or diisopropylethylamine
- organic solvent such as dichloromethane
- the method of preparation, as defined above, of a compound of formula (IV) comprises:
- n 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12
- Y is a protecting group for amines, especially Boc or Fmoc.
- n 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, or
- an acid salt derived from a compound of formula (XXI) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH),
- GP represents a Leaving Group such as -SR, -NTf or -N and Y represents a protective group of amines, in particular Boc or Fmoc,
- n 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12
- Y is a protecting group for amines, especially Boc or Fmoc.
- n 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, or
- an acid salt derived from a compound of formula (IV) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH).
- the invention relates to the compound of formula (X ') below in which: n represents an integer from 1 to 12, especially from 1 to 8, m and m 'independently of one another represent integers from 2 to 8, q and q' independently represent one on the other integers from 0 to 2, - p and p 'independently of one another represent integers from 0 to 4,
- a and A 'independently of one another represent an NH group or a group
- R is an alkyl group of 1 to 3 carbon atoms, linear or branched
- B and B ' represent, independently of one another, an oxygen atom or a CH 2 group
- R and R 'independently of one another represent a halogen, such as chlorine, bromine, iodine or fluorine, or an alkyl group of 1 to 3 carbon atoms, linear or branched, Y represents a protective group amines, especially Boc or Fmoc.
- n 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12
- Y is a protecting group for amines, especially Boc or Fmoc.
- linear or branched alkyl group of 1 to 3 carbon atoms denotes methyl, ethyl, n-propyl and isopropyl groups.
- the compound of formula (X ') as defined above is an intermediate for the preparation of compounds of formula (I) such that defined above, and the compound of formula (XX) as defined above is an intermediate for the preparation of compounds of formula (IV) as defined above.
- XXX wherein X 1 and X 'are, independently of each other, a halogen, especially chlorine, bromine or iodine, n represents an integer from 1 to 12; , especially from 1 to 8,
- n represents an integer from 1 to 8
- q represents an integer from 0 to 2
- p represents an integer of 0 to 4
- R represents a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched,
- R ' represents a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched, steps a) and b) can be performed simultaneously ("one pot" reaction) or successively,
- n represents an integer from 1 to 12, especially from 1 to 8, m and m 'independently of one another represent integers from 1 to 8, q and q' independently represent one of the other of integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4, R and R' are independently of each other a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched,
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'independently of one another represent integers from 1 to 8, and q' and q 'independently represent one of the other of integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4,
- R and R' are independently of each other a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched, or a physiologically acceptable acid salt derived from a compound of formula (Ic) such as a hydrochloride, a formate, a trifluoroacetate or an oxalate (HOOCCOOH).
- the Pinner reaction comprises two steps: a reaction of the nitrile function with ethanol in the presence of acid, in particular hydrochloric acid, followed by a reaction with ammonia, to result in the formation of the amidine function .
- n represents an integer from 1 to 12, especially from 1 to 8, q and q 'independently of one another represent integers from 0 to 2, p and p' independently represent one on the other, whole numbers from 0 to 4,
- R and R ' are, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched,
- n represents an integer from 1 to 12, especially from 1 to 8, q and q 'independently of one another represent integers from 0 to 2, p and p' independently represent one of other integers from 0 to 4, R and R 'are, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine, or an alkyl group of 1 to 3 carbon atoms, linear or branched,
- X represents a leaving group, in particular a halogen atom such as the chlorine, bromine or iodine atoms
- n represents an integer from 1 to 12, especially from 1 to 8, m and m 'independently of one another represent integers from 1 to 8, q and q' independently represent one on the other integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4,
- R and R ' are, independently of one another, a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched,
- n represents an integer from 1 to 12, in particular from 1 to 8, m and m 'independently of one another represent integers from 1 to 8, and q' and q 'independently represent one of the other of integers from 0 to 2, p and p 'independently of one another represent integers from 0 to 4,
- R and R' are independently of each other a halogen, such as chlorine, bromine, iodine or fluorine atoms, or an alkyl group of 1 to 3 carbon atoms, linear or branched,
- a physiologically acceptable acid salt derived from a compound of formula (Id) such as hydrochloride, formate, trifluoroacetate or oxalate (HOOCCOOH).
- the residual aqueous phase is added with 40 ml of AcOEt, and the pH of the mixture is lowered to 7-8 using an aqueous solution of 1M HCl.
- the phases are then separated and the aqueous phase is washed with AcOEt (2 * 15 mL).
- the combined organic phases are then dried over Na 2 SO 4 , filtered and evaporated.
- the crude is then purified by chromatographic column (Al 2 O 3 , CH 2 Cl 2 / Hex, 85:15) to give N- (t-butoxycarbonyl) -2- (4-hydroxyphenyl) ethylamine (0.98 g 73%).
- N- (t-butoxycarbonyl) -2- (4-hydroxyphenyl) ethylamine (1.5 g, 6.32 mmol, leq) is dissolved in CH 3 CN (freshly distilled over CaH 2 ) and added with K 2 CO 3 (1.74 g, 12.64 mmol, 2 eq).
- the mixture is refluxed under argon for about two hours before the addition of dichlorohexane (0.55 mL, 3.79 mmol, 0.6 eq.). After 24 hours at reflux, 0.3 equivalents of dichloro-hexane are added. After 48 hours of reaction, the return to ambient temperature is followed by evaporation of the solvent.
- the crude obtained is solubilized in CH 2 Cl 2 and filtered on sintered glass to remove the mineral impurities.
- the filtrate is then concentrated to a minimum of solvent and precipitated by addition of MeOH accompanied by cold evaporation.
- the solid obtained is then filtered, rinsed with MeOH and dried under vacuum. It corresponds to the expected compound in the form of a white powder (0.52 g;
- a variant using DMF or another amide (dimethylacetamide, N-methylpyrrolidone for example) as solvent is applicable at room temperature.
- UV-Vis H 2 O: 195 (9326.7); 221 (2238.7).
- 1,6-bis (4- (2-guanidinoethyl) phenoxy) hexane using respectively diiodomethane, dibromopropane, dibromobutane, dibromopentane, dibromoheptane, dibromooctane, dibromononane, dibromodecane and dibromdodecane in place of dichloro-hexane), or the corresponding dichloro-, dibromo-, diiodo or di-para-toluenesulfonylalkanes.
- 1,7-bis (4- (2-guanidinoethyl) phenoxy) heptane compound 1H-NMR (400 MHz, D 2 O): 1.42 (m, 6H, OCH 2 CH 2 CH 2 ); 1.72 (m, 4 ⁇ ,
- Variants using DMF in the presence of NaH at 50 ° C. or CH 3 CN in the presence of K 2 CO 3 at 90 ° C. are also applicable.
- the bis-propionitrile previously obtained is hydrolyzed in a mixture of acetic acid / concentrated sulfuric acid / water at approximately 100 ° C.
- the addition of cold water precipitates the diacid which is collected by filtration, washed with water and dried under water. empty.
- This diacid is then converted into ethyl diester by treatment with a mixture of concentrated sulfuric acid / ethanol at reflux, followed by precipitation by addition of water, filtration, washing with water and drying, then chromatography if necessary.
- An alternative to this esterification may be the reaction of the diacid with two equivalents of KOH (or CsOH) in water, followed by lyophilization, yielding the double potassium salt (or cesium).
- This salt is reacted with about two equivalents of ethyl halide (or tosylate or mesylate) in anhydrous dimethylformamide.
- an excess of ice water is added to give a precipitate of the diester (or a gum) which is separated by filtration (or decantation).
- the crude bis (4- (2- (ethoxycarbonyl) ethyl) phenoxy) alkane diester is purified by chromatography.
- the ethyl diester previously obtained is treated in anhydrous THF (or diethyl ether) with one equivalent of lithium aluminum hydride.
- a chromatographic control incorporating a treatment of the sample according to the standard of this reaction is carried out before stopping the reaction.
- Excess hydride is destroyed by careful addition of water, or ethyl acetate.
- the solid residue is removed by filtration, and evaporation of the filtrate in vacuo gives the desired bis (4- (hydroxypropyl) phenoxy) alkane.
- the latter can be purified on a short column of silica or alumina.
- the bis (4- (hydroxypropyl) phenoxy) alkane above is solubilized in dichloromethane, with two equivalents of triphenylphosphine.
- the solution is cooled to 0 ° C., and an excess of carbon tetrachloride is added.
- the reaction medium is stirred at room temperature and the reaction is monitored by chromatography; when all the diol has disappeared, the solvents are evaporated and the residue is chromatographed on silica or alumina to give the desired bis (4- (chloropropyl) phenoxy) alkane.
- the dibromo derivative can be obtained in a similar manner by replacing carbon tetrachloride with carbon tetrabromide.
- a synthetic alternative may be the addition of an excess of thionyl chloride at 0 ° C. to a solution of diol in anhydrous dichloromethane.
- the reaction is monitored by chromatography. When the alcohol is consumed, the solvent and the excess of thionyl chloride are distilled or evaporated under vacuum, to give the crude dichlorinated derivative, which can be chromatographed.
- the above bis (4- (chloropropyl) phenoxy) alkane is dissolved in dry dimethylsulfoxide, and sixteen equivalents of potassium cyanide (or sodium) are added all at once.
- the mixture is heated under an inert atmosphere at 80 ° C.
- the reaction is monitored by chromatography. When all the dichlorinated derivative has been consumed, the mixture is cooled to room temperature and ice water is added to give a precipitate (or gum), isolated by filtration or decantation. After drying, the solid or gum obtained is chromatographed to give the desired bis (4- (cyanopropyl) phenoxy) alkane.
- the solid obtained is solubilized in a minimum of CH 2 Cl 2 and again precipitated by the addition of an excess of MeOH. After filtration, washing with MeOH and drying, the pure expected compound is obtained in the form of white flakes (0.45 g, 41%).
- Variants using DMF in the presence of NaH at 50 ° C. or CH 3 CN in the presence of K 2 CO 3 at 90 ° C. are also applicable.
- 1,10-Bis (4- (2-cyanoethyl) phenoxy) decane are prepared following the procedures described above to give 1,1-bis (4- (2-cyanoethyl) phenoxy) methane (respectively using dibromopropane, dibromobutane, dibromopentane, dibromohexane, dibromoheptane, dibromooctane, dibromononane and dichlorodecane in place of dichloromethane), or the corresponding dichloro- or diiodo or di-para-toluenesulfonylalkanes.
- a solution of a bis (4- (cyanoalkyl) phenoxy) alkane derivative in a mixture of ethanol and anhydrous benzene is cooled to 0 ° C. and is then treated by bubbling gaseous hydrochloric acid for approximately 1 hour.
- the acid solution is stored at 4 ° C for several days.
- the volatile portion of hydrochloric acid is removed by bubbling dry nitrogen, and the degassed solution is evaporated to dryness under reduced pressure.
- the evaporation residue containing bis (4- (ethyl) imidatoalkyl) phenoxy alkane dihydrochloride is taken up in an IM solution of ammonia in ethanol.
- the mixture is heated at 50-60 ° C. under anhydrous conditions during 2-3h, then left stirring at room temperature overnight.
- the resulting medium is filtered and then diethyl ether is added, precipitating the desired bis (4- (amidinoalkyl) phenoxy) alkane dihydrochloride.
- the bis (4- (cyanoalkyl) phenoxy) alkane compound is dissolved in an EtOH / benzene mixture and is bubbled under stirring at 4 ° C HCl gas for about two hours. The mixture is then left stirring at room temperature for 48 hours before the evaporation in vacuo of the solvents.
- the oil obtained is then solubilized in a minimum of EtOH and the expected bis-imidate is precipitated by addition of a large excess of Et2O.
- the white precipitate is then filtered on frit, washed with Et 2 O and dried under vacuum.
- the desired compound is obtained in the form of a white powder.
- EtOH and gaseous NH 3 was bubbled for about 1 h 30 min.
- the medium is then refluxed under argon for 5 to 6 hours.
- the return to ambient temperature is followed by the precipitation of the bis-amidine salt by adding an excess of Et 2 O in the medium.
- the precipitate is filtered, washed with ether and dried under vacuum.
- the expected product is obtained in the form of a white powder.
- the 1,2-diphenylalkane is treated with dichloromethylether in the presence of zinc chloride (Hager et al., J. AM Pharm Ass, 1952, XLI, 3 (6), 115-118, Reichstein and Oppenauer, HeIv. Chim. Acta, 1933, 16, 1380) or with chloromethyl-n-octyl ether in the presence of titanium tetrachloride, or any other chloromethylating agent, to give bis (para-chloromethyl) -diphenylalkane.
- zinc chloride Hager et al., J. AM Pharm Ass, 1952, XLI, 3 (6), 115-118, Reichstein and Oppenauer, HeIv. Chim. Acta, 1933, 16, 1380
- chloromethyl-n-octyl ether in the presence of titanium tetrachloride, or any other chloromethylating agent, to give bis (para-chloromethyl) -diphenylalkane.
- Bis (para-chloromethyl) -diphenylalkane is treated with NaCN in a hydroalcoholic mixture (Hager et al., J. AM Pharm Ass, 1952, XLI, 3 (6), 115-118, Reichstein and Oppenauer, HeIv. Chim. Acta, 1933, 16, 1380), or in any other solvent promoting this nucleophilic substitution to give the bis (para-cyanomethyl) -diphenylalkane
- the bis (4-cyanoalkyl) -diphenylalkane in question is dissolved in anhydrous THF under an inert atmosphere.
- borane complex 1M THF in tetrahydrofuran are added, and the mixture is stirred for 30 minutes at room temperature and then brought to reflux for 3 to 4 hours. After cooling to room temperature, the mixture is added to excess methanol to destroy the excess borane. Trimethoxyborane, methanol and tetrahydrofuran are evaporated. The evaporation residue is taken up in a methanol / water / hydrochloric acid mixture, and the mixture is refluxed for 2 hours.
- the solvents are evaporated to dryness to give the desired bis (4 - ((aminomethyl) alkyl) diphenylalkane dihydrochloride
- the free bisamine is obtained by treatment of an aqueous solution of hydrochloride in the presence of a mineral base, followed by The organic phase is dried over sodium sulphate, filtered and evaporated under reduced pressure.
- the bis (4-aminoalkyl) phenyl alkane dihydrochloride is suspended in anhydrous CH 2 Cl 2 and solubilized by the addition of a minimum of MeOH. Triethylamine is then added, as well as ⁇ /, N'-Bis (tert-butoxycarbonyl) -N "-triflylguanidine and the whole is placed at room temperature, under an inert atmosphere and with stirring. The solvent is removed by evaporation under The crude product obtained is solubilized with CH 2 Cl 2 , washed with an aqueous solution of 2M NaHSO 4 , then with a saturated aqueous solution of NaHCO 3, and the organic phase is then dried over Na 2 SO 4 , filtered, concentrated and dried. under vacuum to give the protected compound.
- a solution of a bis (4- (cyanoalkyl) phenyl) alkane derivative in a mixture of ethanol and anhydrous benzene is cooled to 0 ° C. and is then treated by bubbling gaseous hydrochloric acid for approximately 1 hour.
- the acid solution is stored at 4 ° C for several days.
- the volatile portion of hydrochloric acid is removed by bubbling dry nitrogen, and the degassed solution is evaporated to dryness under reduced pressure.
- the evaporation residue, containing bis (4- (ethyl) imidatoalkyl) phenyl) alkane dihydrochloride is taken up in an IM solution of ammonia in ethanol.
- Escherichia coli ATCC 25922 Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 25923 & ATCC 29213 and Enterococcus faecalis ATCC 29212 .
- the study also included 5 clinical isolates obtained from rectal swabs and / or blood culture:
- EfR2 E. faecalis resistant to teicoplanin and vancomycin (van A gene)
- PaR1 P. aeruginosa overexpressing an efflux pump
- the isolates were chosen on the basis of their resistance profile. Resistance profiles were determined on VITEK2 (BioMerieux, France).
- the bacteria are cultured either on Mueller-Hinton agar (Difco, 225250) or Mueller-Hinton broth (Difco, 275730), at 35 ° C (Grare M, Mourer M, Fontanay S, Regnouf- de- Vains JB, Finance C, Duval RE.
- Gram M Mourer M
- Fontanay S Regnouf- de- Vains JB
- Finance C Duval RE.
- In vitro activity of para-guanidinoethylcalix [4] arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria. J.
- the different molecules tested were prepared in the form of aqueous solution at 10 -2 mol / l.
- the solutions used for the biological tests are freshly prepared and stored for a maximum of one week at 4 ° C.
- the solutions are filtered through a 0.22 ⁇ m pore filter (Millex®GP, 0.22 ⁇ m, Millipore, France) before each test.
- guanidino compounds 1, 3, 4, 6, 7, 9 and 10 in the form of trifluoroacetic acid salts, amidino compounds 103, 104, 106, 107, 108 and 110 in the form of salts.
- MICs Minimum Inhibitory Concentrations
- bacterial suspensions are prepared from an isolated colony taken from Mueller-Hinton agar taken up in 5 mL of Mueller-Hinton broth. After 24 hours of growth, the bacterial suspensions are diluted in sterile distilled water to obtain an inoculum of 10 5 - 10 6 CFU / mL. The purity of the bacterial suspensions is controlled by agar isolation and Gram stain.
- the MICs are determined using an ELISA plate reader (at 540 nm, Multiskan EX, Thermo Electron Corporation, France) as the concentrations of active substance for the absorbance is comparable to that of the negative control (culture medium alone or with the drug, without the inoculum). The results are the average of 4 independent experiments.
- MIC Minimum inhibitory concentrations
- Table 3.1 MIC values (mg / L) obtained by the liquid microdilution method, according to the procedures of CLSI and CA-SFM.
- Table 3.2 MIC values (mg / L) obtained by the liquid microdilution method, according to the procedures of CLSI and CA-SFM.
- both hexamidine and chlorhexidine have broad-spectrum antibacterial activity (ie, antibacterial activity against Gram-positive and Gram-negative bacteria), with these two molecules (hexamidine and chlorhexidine) having a lower activity on P. aeruginosa.
- hexamidine and chlorhexidine exhibit comparable antibacterial activity whether reference bacteria (ATCC strains) or clinical isolates are considered.
- hexamidine and chlorhexidine show better activity on gram-positive shells (S. aureus and Enterococcus spp., With the exception of chlorhexidine with respect to E. coli bacteria.
- These molecules show activity on Gram-positive and Gram-negative bacteria, with a higher activity on Gram-positive cocci (and more particularly Staphylococcus spp., And S. aureus), and 6 maintain comparable activity on isolates. clinics.
- Compound 6 exhibits an overall antibacterial activity better than hexamidine and comparable to that of chlorhexidine, in particular as regards its activity with respect to Staphylococci.
- Compounds 9 and 10 both show very good activity on the 5 reference strains tested, equivalent or superior to those of compound 6.
- the eukaryotic cells used in our study are the HaCaT cells (human keratinocytes) which were rationally provided by the Pierre Fabre Institute (Toulouse, France); and MRC-5 cells (human embryonic fibroblasts) which were obtained from BioMerieux (Lyon, France). These cells are grown in DMEM ("Dulbecco's Modified Eagle's Medium", Invitrogen 61965) for HaCaT cells, and MEM ("Modified Eagle's Medium", Invitrogen 41090); 10% fetal calf serum (SVF, Invitrogen, 10270, Lot 40Q5150K) in a humid chamber at 37 ° C. under 5% CO 2 .
- the cytotoxicity test is based on the incorporation of a vital dye, Neutral Red, into the lysosomes of viable cells, following exposure of the cells to the different concentrations of the test molecules.
- the amount of dye, after extraction from the lysosomes, is quantified using a spectrophotometer and compared to that obtained in the case of "control" cells, not exposed to the test molecules.
- the medium contained in each of the wells is removed and replaced with 200 ⁇ L medium without phenol red (Invitrogen, 51200) containing 50 ⁇ g. / mL Neutral Red for an additional 3 h incubation.
- the cells are then rinsed 3 times with a solution of PBS. After the last PBS wash, 200 ⁇ L of a 1% acetic acid / 50% ethanol solution is added to each of the wells to extract the dye from the viable cell lysosomes.
- Absorbance is measured at 540 nm, with a reference wavelength at 690 nm, using an ELISA plate reader (Multiskan EX, Thermo Electron Corporation, France). The results are the average of the values obtained for 8 wells per concentration and per time unit. Each experiment was performed 3 times.
- Table 4 IC 50 determined from the values obtained by the viability test (at MTT). HaCaT and MRC-5 cell lines were cultured as an adherent culture on 96-well microplates.
- the compounds were added at concentrations of 1 to 256 mg / L for 24, 48 and 168 h.
- IC50s are representative of three independent determinations.
- Table 5 CC50 determined from the values obtained by the cytotoxicity test (at RN). HaCaT and MRC-5 cell lines were cultured as an adherent culture on 96-well microplates.
- the compounds were added at concentrations of 1 to 256 mg / L for 24, 48 and 168 h.
- CC50s are representative of three independent determinations.
- Table 6 Selectivity index obtained for 5 reference strains, after 24 hours of exposure to the compound, on HaCaT cell lines. (1,1,6-bis (4- (2-guanidinoethyl) phenoxy) hexane.
- the IS values are globally very close to each other, which shows the interest of compound 6 vis-à-vis "commercial” compounds widely advocated "in town and in hospital” for Gram bacteria infections. positive, and more particularly S. aureus infections.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0803940A FR2933692B1 (fr) | 2008-07-10 | 2008-07-10 | Nouveaux composes, leur utilisation comme medicaments, et leur procede de preparation |
PCT/FR2009/051388 WO2010004231A2 (fr) | 2008-07-10 | 2009-07-10 | Nouveaux composes, leur utilisation comme medicaments, et leur procede de preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2303837A2 true EP2303837A2 (fr) | 2011-04-06 |
Family
ID=40289121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09794039A Withdrawn EP2303837A2 (fr) | 2008-07-10 | 2009-07-10 | Nouveaux composes, leur utilisation comme medicaments, et leur procede de preparation |
Country Status (6)
Country | Link |
---|---|
US (1) | US8703825B2 (fr) |
EP (1) | EP2303837A2 (fr) |
CA (1) | CA2730304A1 (fr) |
FR (1) | FR2933692B1 (fr) |
NZ (1) | NZ591021A (fr) |
WO (1) | WO2010004231A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012147092A2 (fr) * | 2011-03-03 | 2012-11-01 | Cadila Healthcare Limited | Nouveaux sels d'un inhibiteur de la dpp-4 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB938042A (en) * | 1961-03-30 | 1963-09-25 | Wellcome Found | Phenoxyalkanes |
US3896235A (en) * | 1970-09-01 | 1975-07-22 | Burroughs Wellcome Co | Anthelmintic ethers and composition thereof |
DE2658329C2 (de) * | 1976-12-23 | 1983-01-13 | Hoechst Ag, 6000 Frankfurt | Nitroaminäther, Verfahren zu ihrer Herstellung und ihre Verwendung als Disazoverbindungen |
MXPA04001153A (es) * | 2001-08-31 | 2005-02-17 | Neurochem Int Ltd | Derivados de amidina para tratar la amiloidosis. |
JP2006501160A (ja) * | 2002-06-07 | 2006-01-12 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | アミロイド症を処置するためのアミジン誘導体 |
-
2008
- 2008-07-10 FR FR0803940A patent/FR2933692B1/fr active Active
-
2009
- 2009-07-10 US US13/003,330 patent/US8703825B2/en not_active Expired - Fee Related
- 2009-07-10 NZ NZ591021A patent/NZ591021A/xx not_active IP Right Cessation
- 2009-07-10 CA CA2730304A patent/CA2730304A1/fr not_active Abandoned
- 2009-07-10 WO PCT/FR2009/051388 patent/WO2010004231A2/fr active Application Filing
- 2009-07-10 EP EP09794039A patent/EP2303837A2/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2010004231A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2730304A1 (fr) | 2010-01-14 |
FR2933692A1 (fr) | 2010-01-15 |
WO2010004231A3 (fr) | 2010-03-04 |
US8703825B2 (en) | 2014-04-22 |
FR2933692B1 (fr) | 2022-12-02 |
US20110184070A1 (en) | 2011-07-28 |
WO2010004231A2 (fr) | 2010-01-14 |
NZ591021A (en) | 2012-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3463295B1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacidegreffe en bout de chaine | |
FI95800C (fi) | Menetelmä terapeuttisesti käyttökelpoisten amino- ja nitrosubstituoitujen trisyklisten yhdisteiden valmistamiseksi | |
US20150018564A1 (en) | Amide compound or salt thereof, biofilm inhibitor, biofilm remover and disinfectant containing the same | |
US10562842B2 (en) | Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment | |
US20190269719A1 (en) | Polyguanidine polymers and methods of use thereof | |
EP0308328A1 (fr) | Dérivés de (benzyl pipéridino)-1 propanol-2, leur préparation, leur utilisation comme antimicrobiens et les produits les contenant | |
EP0087378B1 (fr) | Ethers-oximes d'alcoylaminoalcools comme médicaments, produits nouveaux et procédés pour leur préparation | |
IE61330B1 (en) | Aromatic derivatives, their preparation and their us as antimicrobial agents | |
EP2303837A2 (fr) | Nouveaux composes, leur utilisation comme medicaments, et leur procede de preparation | |
US20060211625A1 (en) | New hybrid oligomers, their preparation process and pharmaceutical compositions containing them | |
TW200407310A (en) | Compounds | |
US10888087B2 (en) | Lactam solubility | |
US20130109663A1 (en) | N6-(ferrocenmethyl)quinazolin-2,4,6-triamina (h2) and the derivatives and prodrugs thereof as antileishmanial, antiprotozoal, antiparasitic and antimicrobial agents | |
RU2004129734A (ru) | Производные изохинолона | |
BRPI0718014A2 (pt) | Composto de amida ou sal do mesmo, e inibidor de formação de biopelícula, removedor de biopelícula e bactericida, cada um utilizando o composto de amida ou sal do mesmo. | |
EP4294820A1 (fr) | Peptides cycliques pénétrant les cellules avec trois résidus hydrophobes ou plus | |
JP2014501750A5 (fr) | ||
CN113227088A (zh) | 单环β-内酰胺化合物在制药中的应用 | |
EP3237015B1 (fr) | Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine | |
AU2002343783B2 (en) | Peptide derivative, pharmaceutically acceptable salt thereof, process for producing the same, and use thereof | |
EP1189933B1 (fr) | Derives de l'echinocandine, leur procede de preparation et leur application comme antifongiques | |
WO2008050858A1 (fr) | Composé amide, son sel et agent d'élimination de biofilm les utilisant | |
US8722719B2 (en) | Amine compound and use for same | |
JP2008184406A (ja) | 医薬組成物 | |
JP2003221353A (ja) | ポリエチレングリコールおよびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110107 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: REGNOUF-DE-VAINS, JEAN-BERNARD Inventor name: MOURER, MAXIME Inventor name: GRARE, MARION Inventor name: DUVAL, RAPHAEL, EMMANUEL |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20130917 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSITE DE LORRAINE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150825 |